Supplemental material
Journal of Medical Economics
Volume 23, 2020 - Issue 3
Diabetes
Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data
Nancy HolekampPepose Vision Institute, Chesterfield, MO, USA; Correspondence[email protected]
http://orcid.org/0000-0001-7850-8515
http://orcid.org/0000-0001-7850-8515, Steven B. DuffVeritas Health Economics Consulting, Inc., Carlsbad, CA, USA; http://orcid.org/0000-0002-0506-2900
http://orcid.org/0000-0002-0506-2900, & Vincent GarmoGenentech, Inc., South San Francisco, CA, USAhttp://orcid.org/0000-0003-3073-0373
http://orcid.org/0000-0003-3073-0373